Diebold Nixdorf Q2 2026: Revenue Climbs 1.7%, Adjusted EBITDA Rises 8%, Full-Year Outlook Reaffirmed
DBD sits 68% above its 52-week low of $53.93.
Summary
Diebold Nixdorf posted Q2 2026 revenue of $930.8M, up 1.7% YoY, with adjusted EBITDA of $120.6M (up 8%) and GAAP EPS of $0.44 (up 33%). The company reaffirmed its full-year 2026 outlook and repurchased $60M in shares.
Key Events · Earnings and Guidance · DBD
-
Q2 Revenue and Earnings Growth
Revenue of $930.8M grew 1.7% YoY; GAAP net income of $16.2M rose 28% YoY; adjusted EBITDA of $120.6M increased 8% YoY with margin expanding 80 bps to 13.0%.
-
Full-Year 2026 Guidance Reaffirmed
Company reiterated outlook: revenue $3.86B-$3.94B, adjusted EBITDA $510M-$535M, free cash flow $255M-$270M, adjusted EPS $5.25-$5.75.
-
Share Repurchase Update
Repurchased ~$60M of common shares in Q2 under the $200M program; ~$57M remaining authorization.
-
Retail Segment Strength
Retail revenue grew >20% YoY for the second consecutive quarter, with double-digit increases across all geographies and point-of-sale unit sales up nearly 170% in Europe.
Analysis · DBD · Technology
A solid quarter for Diebold Nixdorf featured revenue growth, margin expansion, and a 28% jump in net income. Confidence in the second half is underscored by the reaffirmed full-year 2026 guidance. For the second straight quarter, retail revenue surged over 20%, while Banking backlog grew sequentially, offering clear visibility. The company also repurchased $60 million in shares, leaving $57 million under its buyback program. The only wrinkle: free cash flow turned negative due to an inventory build and a one-time German tax payment, but the underlying business trends remain strong.
At the time of this filing, DBD was trading at $90.75 on NYSE in the Technology sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $53.93 to $92.09. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.